In a report released today, David S Macdonald from Truist Financial maintained a Hold rating on Humana (HUM – Research Report). The company’s ...

Barclays analyst Andrew Mok raised the firm’s price target on Humana (HUM) to $270 from $255 and keeps an Equal Weight rating on the shares.

| With budget reconciliation right around the corner, different slices of the healthcare industry have made their views clear on issues like physician pay, ACA subsidies, telehealth flexibilities, ...

Humana executives said the tower will likely remain occupied until the end of the year as employees transition to the new space.

Stock selection in the financials, consumer discretionary, communication services and information technology sectors drove ...

Humana executives laid out a plan Tuesday to return to normal operations after the company disclosed a loss of $5.76 per share on a GAAP basis for the fourth quarter of 2024 on higher revenues.

CEO Jim Rechtin says investing in primary-care expansion remains a priority, albeit one that’s playing second fiddle to ...

Health-care companies fell after disappointing earnings from one health insurer. Shares of Humana slid after the health-insurance firm warned of falling Medicare Advantage membership, and hinted that ...

Despite ongoing questions about the outlook for its Medicare Advantage business, Humana (NYSE: HUM) plans to invest in the growth of its CenterWell ...

The dip came after Humana released its 2024 end of year and fourth quarter earnings, which projected an annual profit of ...